Dosage Forms
- 500 mg, 250 mg and 125 mg tablets
Drug Group
Antibiotic, Cephalosporins
Packaging
- HDPE flacons of 20’s.
Cefuroxime axetil is given by mouth in treatment of pharyngitis, tonsillitis, acute otitis media, acute maxillary sinusitis, acute exacerbations of chronic bronchitis and secondary infections of acute bronchitis, skin and skin structure infections, urinary tract infections, uncomplicated gonorrhea and early Lyme disease.
Cefuroxime axetil is a second-generation cephalosporin antibiotic that inhibits biosynthesis of bacterial cell wall. Cefuroxime has activity against S. pyogenes, S. pneumoniae, H. influenzae, M. catarrhalis, H. parainfluenzae, S. aureus, E. coli, K. pneumoniae, N. gonorrhoeae, and Borrelia burgdorferi.
Cefuroxime is not indicated in patients with history of penicillins, penicillin derivatives, penicillamine and cephalosporins hypersensitivity, and porphyria. There is evidence of partial cross-allergenicity; cephalosporins cannot be assumed to the absolutely safe alternative to penicillin in the penicillin-allergic patients. Cefuroxime tablets contain phenylalanine and should not be used by phenylketonurics. Cefuroxime should be used with caution in patients with a history of GI diseases, particularly colitis. Cephalosporins may be nephrotoxic, use with caution in the presence of markedly impaired renal function.
Diarrhea, nausea and vomiting have occurred in some patients. Jarisch-Herxheimer reaction, rashes, pruritus and urticaria have been reported. Mild-to-moderate hearing loss reported in some pediatric patients. Hypoprothrombinemia has been reported.
Cefuroxime crosses the placenta. Use only when potential benefits outweigh potential hazards to the fetus. Because Cefuroxime is distributed into milk, Cefuroxime axetil should be used with caution in nursing women.
Probenecid increases cephalosporin serum concentrations, resulting prolonged elimination half-life, and increased risk of toxicity. Concurrent use of diuretics and Cefuroxime may increase the risk of adverse renal effects. The concomitantly use of Cefuroxime and an aminoglycoside may potentiate nephrotoxicity. Plasma concentration of Cefuroxime may be reduced by coadministration of H2-antagonists, decreasing the antibiotic effect. Nonsteroidal anti-inflammatory drugs [NSAIDs], salicylates, or sulfinpyrazon may increase the risk of hemorrhage. Cefuroxime axetil may produce false-positive urine glucose reactions with copper-reduction tests. Cefuroxime may cause a false-negative reaction in the ferricyanide test for blood glucose.
